T-Cell Lymphoma Clinical Trial
Official title:
Phase I Study of CHOP Plus Campath (C-CHOP) for the Treatment of T-Cell, Null-Cell, and NK-Cell Lymphomas
Primary Objective:
- To determine the toxicity profile and tolerability of alemtuzumab (Campath) when
administered in combination with cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) chemotherapy (C-CHOP) in patients with T-cell, null-cell and NK-cell
lymphomas.
Secondary Objectives:
- To evaluate response rate, overall survival, and disease-free survival in patients with
T-cell, null-cell, and NK-cell lymphomas treated with Campath + CHOP chemotherapy.
- To assess the incidence of cytomegalovirus (CMV) reactivation in patients with these
lymphomas treated with the Campath + CHOP combination.
- To determine features which might be predictive of resistance to treatment or
predictive of relapse, including the absence of glycosylphosphatidylinositol
(GPI)-linked proteins.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00959686 -
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT04712864 -
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT01941680 -
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
|
||
| Recruiting |
NCT05075460 -
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
|
Phase 3 | |
| Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
| Completed |
NCT02017613 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
|
Phase 1 | |
| Enrolling by invitation |
NCT01854112 -
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
|
N/A | |
| Completed |
NCT01553786 -
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
|
Phase 2 | |
| Completed |
NCT00542919 -
A Study for Patients With Non-Hodgkin's Lymphomas
|
Phase 2 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Active, not recruiting |
NCT03952078 -
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT05387226 -
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT02424045 -
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT01871675 -
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT00893516 -
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
|
Phase 2 | |
| Completed |
NCT01902225 -
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT02086591 -
A Phase II Study of Doxycycline in Relapsed NHL
|
Phase 2 | |
| Recruiting |
NCT04264078 -
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
|
Early Phase 1 | |
| Completed |
NCT00001582 -
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
|